A phase II study of Oxaliplatin Reintroduction in patients pretreated with Oxaliplatin and Irinotecan for Advanced Colorectal Cancer
- Conditions
- Metastatic colorectal cancer
- Registration Number
- JPRN-UMIN000004884
- Lead Sponsor
- Japanese foundation for cancer research
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 33
Not provided
1.Severe peripheral neuropathy. 2.History of the serious hypersensitivity for drugs. 3.Active infection. 4.Complications (Evidence of interstinal lung disease, emphysema, pulmonary fibrosis, paralytic or mechanical bowel obstruction, uncontrolled hypertension, uncontrolled diabetes mellitus, cirrhosis, active cardiovascular disease, or past or current history (within 3 months) of myocardial infarction, uncontrolled angina pectoris or arrythmia. 5.Multiple primary cancer within 5years. 6.Need to drain pleural effusion, ascites or pericardial effusion. 7.Uncontrolled diarrhea. 8.Radiological evidence of brain cancer. 9.Clinically significant mental or psychological disease. 10.Other conditions not suitable for this study.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Disease control rate after 12 weeks of treatment.
- Secondary Outcome Measures
Name Time Method Adverse Effect Response Rate Progression-Free Survival Overall Survival